Literature DB >> 6150687

Maternal drug histories and central nervous system anomalies.

K A Winship, D A Cahal, J C Weber, J P Griffin.   

Abstract

Prescription data for the three months before the last menstrual period and for the first trimester of pregnancy were obtained for 764 mothers whose children had a defect of the central nervous system and for an equal number of mothers of control babies born from the same doctors' practices. There was a statistically significant difference overall between the numbers of mothers who were prescribed drugs in the study and control groups during the trimester before the last menstrual period but no such difference was found for the first pregnancy trimester, nor was there a significant difference for any specific group of drugs. For a composite group of non-steroid anti-inflammatory drugs, salicylates, and sulphasalazine there was a significant difference for the trimester before the last menstrual period. There are arguments against such an artificial grouping, however, and when the individual drugs were considered the comparisons were no longer significant. The odds ratios for all medicines containing folic acid taken in the trimester before the last menstrual period were considerably less than unity, in contrast with nearly all other comparisons. This supports a suggested protective effect against neural tube defects of folic acid supplements begun before the onset of pregnancy but the odds ratios of these comparisons were not statistically significant.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6150687      PMCID: PMC1628833          DOI: 10.1136/adc.59.11.1052

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  24 in total

1.  Antenatal exposure to doxylamine succinate and dicyclomine hydrochloride (Benedectin) in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score.

Authors:  S Shapiro; O P Heinonen; V Siskind; D W Kaufman; R R Monson; D Slone
Journal:  Am J Obstet Gynecol       Date:  1977-07-01       Impact factor: 8.661

2.  Further experience of vitamin supplementation for prevention of neural tube defect recurrences.

Authors:  R W Smithells; N C Nevin; M J Seller; S Sheppard; R Harris; A P Read; D W Fielding; S Walker; C J Schorah; J Wild
Journal:  Lancet       Date:  1983-05-07       Impact factor: 79.321

3.  Possible embryotoxicity of sulfasalazine.

Authors:  A Craxi; F Pagliarello
Journal:  Arch Intern Med       Date:  1980-12

4.  Incidence of neural-tube defects.

Authors:  B Field; C Kerr; C D Mathers
Journal:  Dev Med Child Neurol       Date:  1982-12       Impact factor: 5.449

5.  Placental and mammary transfer of sulphasalazine.

Authors:  A K Khan; S C Truelove
Journal:  Br Med J       Date:  1979-12-15

6.  Current trends in the incidence of neural tube defects.

Authors:  G C Windham; L D Edmonds
Journal:  Pediatrics       Date:  1982-09       Impact factor: 7.124

7.  Aspirin and congenital malformations.

Authors:  D Slone; V Siskind; O P Heinonen; R R Monson; D W Kaufman; S Shapiro
Journal:  Lancet       Date:  1976-06-26       Impact factor: 79.321

8.  Apparent prevention of neural tube defects by periconceptional vitamin supplementation.

Authors:  R W Smithells; S Sheppard; C J Schorah; M J Seller; N C Nevin; R Harris; A P Read; D W Fielding
Journal:  Arch Dis Child       Date:  1981-12       Impact factor: 3.791

9.  Possible teratogenicity of sulphasalazine.

Authors:  N M Newman; J F Correy
Journal:  Med J Aust       Date:  1983-05-28       Impact factor: 7.738

10.  Outcome of pregnancy in women using different methods of contraception.

Authors:  M Vessey; L Meisler; R Flavel; D Yeates
Journal:  Br J Obstet Gynaecol       Date:  1979-07
View more
  9 in total

1.  Anencephaly with placental attachment.

Authors:  C K Sasidharan; P Anoop
Journal:  Indian J Pediatr       Date:  2002-11       Impact factor: 1.967

2.  Periconceptional vitamin supplementation and neural tube defects; evidence from a case-control study in Western Australia and a review of recent publications.

Authors:  C Bower; F J Stanley
Journal:  J Epidemiol Community Health       Date:  1992-04       Impact factor: 3.710

Review 3.  Anticoagulant therapy and pregnancy.

Authors:  Aiko Makino; Mayumi Sugiura-Ogasawara
Journal:  Reprod Med Biol       Date:  2008-02-01

4.  Vitamins and neural tube defects.

Authors:  J P Griffin
Journal:  Br Med J (Clin Res Ed)       Date:  1988-02-06

5.  Maternal drug histories and congenital malformations: limb reduction defects and oral clefts.

Authors:  L Hill; M Murphy; M McDowall; A H Paul
Journal:  J Epidemiol Community Health       Date:  1988-03       Impact factor: 3.710

6.  Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies.

Authors:  L R Dolovich; A Addis; J M Vaillancourt; J D Power; G Koren; T R Einarson
Journal:  BMJ       Date:  1998-09-26

7.  Folic acid fortification of grain: an economic analysis.

Authors:  P S Romano; N J Waitzman; R M Scheffler; R D Pi
Journal:  Am J Public Health       Date:  1995-05       Impact factor: 9.308

Review 8.  Sleep Pharmacotherapy for Common Sleep Disorders in Pregnancy and Lactation.

Authors:  Margaret A Miller; Niharika Mehta; Courtney Clark-Bilodeau; Ghada Bourjeily
Journal:  Chest       Date:  2019-10-14       Impact factor: 9.410

9.  Inter-Regional Epidemiological Study of Childhood Cancer (IRESCC): childhood cancer and the consumption of debendox and related drugs in pregnancy.

Authors:  P A McKinney; R A Cartwright; C A Stiller; P A Hopton; J R Mann; J M Birch; A L Hartley; J A Waterhouse; H E Johnston
Journal:  Br J Cancer       Date:  1985-12       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.